Search

Displaying results 3491 - 3500 of 10000 in total
  1. Drug

    Etilefrine

    go.drugbank.com/drugs/DB08985
    ApprovedWithdrawn

    Etilefrine is an adrenergic agonist that appears to interact with beta-1 and some alpha-adrenergic receptors. It has been used as a vasoconstrictor agent.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Sotatercept

    go.drugbank.com/drugs/DB12118
    ApprovedInvestigational

    [L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP pathway signalling observed in PAH. … It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain.

    Synonyms: (HUMAN ACTIVIN RECEPTOR TYPE-2A PRECURSOR-(21-135)-PEPTIDYL)-THREONYLTRIGLYCYL-(HUMAN IMMUNOGLOBULIN HEAVY CONSTANT .GAMMA.1 FC FRAGMENT: (8-15)-HINGE-(A-100>V)-CH2-CH3 OF HOMO SAPIENS IGHG1*03), (123-, (HUMAN ACTIVIN RECEPTOR TYPE-2A PRECURSOR-(21-135)-PEPTIDYL)-THREONYLTRIGLYCYL-(HUMAN IMMUNOGLOBULIN HEAVY CONSTANT .GAMMA.1 FC FRAGMENT: (8-15)-HINGE-(A-100>V)-CH2-CH3 OF HOMO SAPIENS IGHG1*03), (123-
  3. Drug

    Tocotrienol

    go.drugbank.com/drugs/DB12647
    Investigational

    Tocotrienol has been investigated for the treatment of Cholesterol Lowering.

    Mixtures: NHF Tocotrienol E Plus Vitamin D3 SoftgelCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    OXI-4503

    go.drugbank.com/drugs/DB05143
    Investigational

    OXI-4503 (combretastatin A1 di-phosphate / CA1P) is a unique and highly potent, dual-mechanism vascular disrupting agent (VDA). … Preclinical studies have demonstrated that OXI-4503 has (i) single-agent activity against a range of xenograft tumor models; and (ii) synergistic or additive effects when incorporated in various combination

    Synonyms: Combretastatin A-1 bis(phosphate)
  5. Drug

    Phentolamine

    go.drugbank.com/drugs/DB00692
    ApprovedInvestigational

    Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. … [L48420, L48415, L48390] Phentolamine is administered intravenously, intramuscularly, submucosally, and topically.

    Synonyms: 2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline
  6. Drug

    Mifepristone

    go.drugbank.com/drugs/DB00834
    ApprovedInvestigational

    Mifepristone is a progestational and glucocorticoid hormone antagonist. … As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome.

  7. Drug

    Endostatin

    go.drugbank.com/drugs/DB06423
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Obecabtagene autoleucel

    go.drugbank.com/drugs/DB17362
    ApprovedInvestigational

    Obecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19. … [L52450] Obecabtagene autoleucel was also investigated in other hematological cancers and systemic lupus erythematosus.[A265045]

    Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING, A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING O
  9. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    [L4168] It was approved for the same indications in Canada in June 2022. … Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of

  10. Drug

    Fedratinib

    go.drugbank.com/drugs/DB12500
    ApprovedInvestigational

    Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. … [A183176,L8090] It is an anilinopyrimidine derivative.[A183188] Fedratinib was granted FDA approval on August 16, 2019.[L8090]